Since elevated expression of AXL and MET are implicated in resistance to antiangiogenic therapy, simultaneously targeting VEGFR2, MET, and AXL with sitravatinib may target multiple aberrant pathways common in RCC and provide antitumor activity [3, 12, 13]. This evidence concerns the gene AXL and renal cell carcinoma.